Payden & Rygel Investment Group’s Bristol-Myers Squibb BMY Stock Holding History

Payden & Rygel Investment Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,800	Closed	-$206K	–	125
2024 Q1	$206K	Buy	+3,800	New	+$194K	0.01%	117
2023 Q3	$221K	Buy	+3,800	New	+$233K	0.02%	118

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Payden & Rygel Investment Group's BMY Position: Q2 2024 in Review

Payden & Rygel Investment Group sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 3,800 shares — an estimated $206K sold.

Payden & Rygel Investment Group first reported a position in BMY in Q3 2023 and held it in 2 quarters. The position peaked at $221K in Q3 2023. 2,147 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Payden & Rygel Investment Group reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Payden & Rygel Investment Group sold 3,800 Bristol-Myers Squibb shares in Q2 2024, an estimated $206K.
Payden & Rygel Investment Group first reported a position in Bristol-Myers Squibb in Q3 2023 and held it in 2 quarters.
Payden & Rygel Investment Group's Bristol-Myers Squibb position peaked at $221K in Q3 2023.
2,147 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Payden & Rygel Investment Group's 13F filing for Q2 2024, filed 12 Aug 2024.